BioSpace News Archive

Graybug Vision, Inc., a clinical stage biopharmaceutical company focused on developing transformative medicines to treat diseases of the retina and optic nerve, announced the early closing of enrollment in its ALTISSIMO trial.

Parallax Health Sciences, Inc. announced in a statement that it reaffirms its plan to manufacture the Company’s VT-1000 qualitative and quantitative immunoassay analyzer for medical use and has already previously been approved through a 510 with the U.S. Federal Drug Administration

Aleafia Health Inc. (TSX: ALEF, OTC: ALEAF, FRA: ARAH) (“Aleafia Health” or the “Company”), is pleased to report its financial results for the 2019 fourth quarter (“Q4 2019”) and fiscal year (“FY 2019”).

MediPharm Labs Corp. a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce it will begin supplying finished pharmaceutical-quality cannabis oil products in Australia as part of a 2 year agreement entered into between MediPharm Labs Australia Pty Ltd and Compass Clinics Australia Pty Ltd...

SciBite announced being named the fastest-growing company identified in this year’s Alantra Pharma Fast 50, an annual ranking of privately-owned pharmaceutical businesses in the UK based on growth speed.

Oncology experts GRYT Health and AAPM launch suite of tools to connect patients to resources

Further expansion of HORAMA gene therapy portfolio to treat Inherited Retinal Dystrophies to lead to second clinical program by 2023

GroupSystems Corp., the leading provider of digital client engagement and workshop facilitation, is expanding on its offer last week to help businesses struggling to maintain momentum during the COVID-19 pandemic.

Clinical combination of IDE196, a PKC inhibitor, and binimetinib, a MEK inhibitor, to be investigated in patients with solid tumors that harbor GNAQ or GNA11 hotspot mutations, including Metastatic Uveal Melanoma, Cutaneous Melanoma, and Colorectal Cancer

ASLAN Pharmaceuticals reported financial results for the quarter and full year ended 31 December 2019 and provided an update on its clinical activities.